ClinicalTrials.gov
ClinicalTrials.gov Menu

Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00090090
Recruitment Status : Completed
First Posted : August 25, 2004
Last Update Posted : January 15, 2008
Sponsor:
Information provided by:
Spectrum Pharmaceuticals, Inc

Brief Summary:
To determine the safety and efficacy of elsamitrucin in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL). To determine if elsamitrucin is efficacious in a particular pathologic NHL subtype(s).

Condition or disease Intervention/treatment Phase
Mantle Cell Lymphoma Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Drug: Elsamitrucin Phase 2

Study Type : Interventional  (Clinical Trial)
Enrollment : 114 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multi-Center, Open-Label, Non-Randomized Phase II Study of Elsamitrucin (SPI 28090) In Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Study Start Date : April 2004
Actual Study Completion Date : October 2006






Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Relapsed or Refractory mantle cell lymphoma and/or CLL/SLL except Burkitt's, Burkitt's like or HIV-associated lymphoma
  • at least one prior cytotoxic chemotherapy regimens
  • measurable disease
  • adequate bone marrow, liver and kidney function
  • ECOG PS 0-2

Exclusion Criteria:

  • prior treatment with elsamitrucin
  • prior chemo, antibody or radiotherapy for NHL within 28 days prior to start to treatment
  • HIV positive or known AIDS syndrome
  • uncontrolled medical disease or psychiatric condition/s

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00090090


Locations
United States, California
Alta Bates Cancer Center
Berkeley, California, United States, 94704
Providence Saint Joseph Medical Center
Burbank, California, United States, 91505
USC Norris Cancer Center
Los Angeles, California, United States, 90033
Tower Hematology Oncology Medical Group
Los Angeles, California, United States, 90048
North Valley Hematology Oncology Medical Group
Mission Hills, California, United States, 91343
Cancer and Blood Institute Medical Group
Rancho Mirage, California, United States, 92270
United States, New York
North Shores University Hospital
Manhasset, New York, United States, 11021
Sponsors and Collaborators
Spectrum Pharmaceuticals, Inc

Publications:
ClinicalTrials.gov Identifier: NCT00090090     History of Changes
Other Study ID Numbers: ELSA 2004-001
First Posted: August 25, 2004    Key Record Dates
Last Update Posted: January 15, 2008
Last Verified: January 2008

Additional relevant MeSH terms:
Lymphoma
Lymphoma, Non-Hodgkin
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Lymphoma, Mantle-Cell
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia
Leukemia, B-Cell
Elsamicin A
Antibiotics, Antineoplastic
Antineoplastic Agents